Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQUTRXMXVnZjVuU0VfdmVzVnRPeUxBZ1pvNEUzS2FIcmlCSXdHNW5FRGxnUWRnVGwzVlh1Y1Y3ckdZczdYMjhKb1dyZ245UVNSbmVJZm55TVRSNVFvYVoyaWF5MktKeEVHN0VmQy1ZUWNBOWNOUXgtVk1NWExkTVlhWkYtTV81TnNVY1RzczlTWHFsYk9hVVlTTw?oc=5" target="_blank">U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes</a>&nbsp;&nbsp;<font color="#6f6f6f">Yahoo Finance</font>
Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats
Levante - Sevilla en directo
"La cosa se está poniendo tensa": manifestantes se enfrentan a agentes migratorios en Oregon
Indigo Girls cancel show after tour bus driver dies in highway crash
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFBfbmlHMGpGNEoyTmNZQkE3R0R6WVBBTGdMTzVfYVZSVklMbktaV3Z4WTE2anZqRHdTcmZsUXhUaFFpbTRjRGRFRTd2ZHE5Tlk1TkprdzA1ZVdHZno5c0IxODQ4SlUyNVN1TFlodHhwUTU?oc=5" target="_blank">FDA Accepts Application for BTK Inhibitor for Multiple Sclerosis</a>&nbsp;&nbsp;<font color="#6f6f6f">Neurology Today</font>
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE8wMldvN0hvcldFX0FTem9uQnNpNUNCMmNxMTY1NjltQ2NFZE1DekJNam1xVXJveEt6UldSc050dkFpQVlDcEFOajB2ZnUtS2xrY1VMcGxnLWY0NHRrb1hoWUVMRmRsXzFINHNBRFUwQ2Y?oc=5" target="_blank">United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis</a>&nbsp;&nbsp;<font color="#6f6f6f">United Therapeutics Investor Relations</font>
<a href="https://news.google.com/rss/articles/CBMi_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?oc=5" target="_blank">U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNdTF1UHNaSGI2QzhrazBucXk2cGVyQV9DX1R3NzNpM2REZl9zY1FuR0ZzdkhTVmxMYjFzdmFsV19GNDVmb2k0SURhQmdQS0pLOTJ5YTlHTHQzMWpwNmttODlFT09PVXdlT0dDS1AwYVQyR05wTEtkZ2x1QklkX2RETy1RVmtFSHU4eXRjMEdpa1JDdw?oc=5" target="_blank">FDA takes applications for new program to shorten drug approval times</a>&nbsp;&nbsp;<font color="#6f6f6f">STAT</font>
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNcm1xWmdaRk92OUcteno0eXZPZGMtMGx6TFFFRTFMeTdhREplR3ZTcE9tVW1ZV1dBdnlIMm9uUFAza2hFeVVMYzFTUHVjNlF6UkpiZXpsd2R5SDBqekQtOXNDXzRwejVIaUNSWDdnd0J4SENLUEhxT0NEa1pUOHZaN0JHSFl0aTNpaUgxUFBzSnFpeEMxbkVFVnlmTlBOZWFRYURQNA?oc=5" target="_blank">FDA accepts application to expand clesrovimab-cfor use to high-risk children in second RSV season</a>&nbsp;&nbsp;<font color="#6f6f6f">Contemporary Pediatrics</font>
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQcHF5VlJQX2RCVUI0djFsbG5GS2NZRXJXQlZwY3R0OE90cHNwSDZTQzFMbVlxTG83eHVYZUdjUk1wdDA3SGVKUzBhZ24wYzJmdUpTN25jbXhDRmozaU5HdTg4eThhY2xxcXAxdndHZGRvWUNFMC0yRkk3MkNJemFual8xMnZ6RTVZT2lWUTFQR3ZncTVVX1QzSW5hQldwTWJ4bUZEdDlKZUM0S2ZGV0VGQmowbw?oc=5" target="_blank">FDA Accepts daraxonrasib Application for RAS-Mutant Pancreatic Cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">The Clinical Trial Vanguard</font>
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOX2hLa09sNnZFTG9yM1I3ZVF4VDNSLWFNOEkwTVhOYXBwanBnZklhLTdJZEFZajVfRFFISWRMSnZiN0hFYkxFblRMaXpMMm90T2ZlOHZYdDFPUUI2LW5na3pPWE9FVG5ETDR5RWwxT1R6YjY3anNUYUNtRXVtZnk0dzZuR2phejNnRFhGSQ?oc=5" target="_blank">US FDA accepts Teva’s new drug application for ecopipam</a>&nbsp;&nbsp;<font color="#6f6f6f">PharmaTimes</font>
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxQTUFsT2xSLW11LWVlTjVRblFRVTNKeHNPZnZ4REVIZ19NTXZDcFZpdmQ2RF9UZnJpNUpDQTJRc1pQcUNSVVVPc0hERUFfMDk1c0V3Rmd5REhDZHoxSmtUcXBxRExhQzh0M2M4VkNINWpxTEpaZG1HUTVJV09RcHd3dmgwMUh5QVpYSUd1Uy1qdmZjYl9tRDdsY1daeG94WTFLUENvMUl5LThWdGFKckJ4M0tPalpZVlhsbnMzNkxhWnhCbjg2QWljOFdncGp3Z3dub2dCeUtORjBkdXZ1T3NBMGc0VDl5Z3NwVUJVeGkxYWJoUmVtNzQ3YWwybVB5WnBGSDVnUHc1TQ?oc=5" target="_blank">U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQVU9aeFJ3eVRqeUU0SjY3cWNoWHRUbjNsVC1uZDVWaklYQmxscDdIdDNlajJfeWlRRjhORXZtem5mSTFRVFphMlFRNFM3Q3lvZFNDMUwweTFHZVI3V1d1TUNJZ0U5MEtYNC16Mzg4WEVRR0xGRVlSQVpyS2ZuMjZ4TXZseGpjc2UxYnlIUW5BSmV4OHAtNU04SWNRVjZRRlMtbWJ0cHZxbjNPdw?oc=5" target="_blank">FDA Grants Priority Review to Dostarlimab in dMMR/MSI-H Rectal Cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQaUpKZjNOV2lON1E5dWNwSjE3TnFhS1l4UjNOeThOTlZZN3g5eHlwdnFEbWhhM0NLOVR2UnppZUt3V0U2OVhER2xpYkNQbGh3ZlROVmpGV2pHcnpSY3ZKQ2tuZ0YxdXlsZ1U5anU3RmJZNTF5M0dqMXhmYXBEMmxoMzRZLTZqZWNaUVBJemZNTG5lXzVmN2Y2Yw?oc=5" target="_blank">FDA Accepts Merck's Application to Expand Enflonsia into Second RSV Season</a>&nbsp;&nbsp;<font color="#6f6f6f">BioPharm International</font>
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVWQ0cktiMllGdGJkRXpHaXp0VVpsMlhDTmxmVS1PbkZjQlNDLUFjT2FuU0w1Y0ZfcDhnTkVwVlRSTC02SWxXbmlib28wbnl2U29Uc011c21xZFdZOHJ1b0YtRUwtdUxmWThWUHZwbGZMaUtieWZ2UEh0LUlVeWVBNUJ4X1pFckFTbEVBU3dHbjFpZHAzd0RPNUlnb0p5Z2U1aUtWODl2SXFXcmozbVI4N21EY3FNZ3c5dld3?oc=5" target="_blank">FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug</a>&nbsp;&nbsp;<font color="#6f6f6f">BioSpace</font>
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQcEM1LWR5dTJTNC14c0RsWi1CT0hMX3p3aW9HeC16QVc1VHR5MnJPT1l1NVdFTWlUTzM0T1JPcHR5MnZwNkNPdE56cUJRSUUtV2c1eGhSQk9iZ1lpcEw4QUdsaFF3bXcyRTFSam4zZ3pyTlZsbDAwZFh1dnZ3NEdNZ3k0UTdCT0Q2bE1WeHZTNFBZMWs5eEZ6cHVCZHcxZHZra1J4R1lpdkU1S2UwQ1lncEJGLW1kUmNLSGhwX2xLUHpETmc?oc=5" target="_blank">FDA accepts application to expand Merck's RSV antibody ENFLONSIA into new season</a>&nbsp;&nbsp;<font color="#6f6f6f">The Pharma Letter</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNaXRiS1VPa2dkTW12RnRTR1ZRTHRoQUhtYU1IX1kxYzUtNTNWREZkLUxvRTA4WGpBall3RTUwRVRYSDV0WkJERm94YTlYOTRSWGtvYXpBQUhsUTk2My10OVdsZFFSb3A0LWt6RVVBdVdicmRTMmJLLUxHeFdWTkRVZUwtMDZqajZzVTh5bmg3Y29KOGk2ZHlzeUxSMElGSW5WYzBRRmZTVkw2UVkxeUI4?oc=5" target="_blank">FDA Accepts NDA, Grants Priority Review to Ecopipam for Pediatric Tourette Syndrome</a>&nbsp;&nbsp;<font color="#6f6f6f">NeurologyLive</font>
<a href="https://news.google.com/rss/articles/CBMi1AJBVV95cUxNMmlWcURFMnl1aTFuVmNYeDdaelk0LWdHSWtQWmR5VllZbjlIRGNkNnNuaGdEOHB3ckZJclpZTFY2ZnRPNkZhQWVRTnFtMjlORmctUFhvV09IVDRCckFqcXAwMDBQM2lOY0N1UHhfWWVWVkJZV0Vza2h1a0xObFdDNE9za3J2d3RLeGxNTHp3UWNVc3FzZjlQdF9YV0c2Rkp4UjRJdDhPb2FnOUw4ZW8tY0FBbjJXeE45Z1RUMG9ITlo1VHZrT2gtUW01MVVhMExKS3lqekpSNE4zS2JObldQMk0xTGdHRGZFSERRaXlBODBlWlhpSTFWVnNtdGw1ZzlfV1hLcW1FSXJLMnpsZG1oTVh0dE04X0o3aFZxOXBNbXZhbklNUjg3ejlyejhjeTAza1hMNW9MNDZ6aHB4R2hldWt6WlJ6S3hJd3dvRlg5Z2t6TzZS?oc=5" target="_blank">U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQRkdFY3F0TzB3UnpKWFg2QjdSQ0JVMXVuQ3NrMnJ0VmlXU0ZmTHJ5aFdGWFVld0ItZEpKVmROVzF3aEZsNFMyX01YV3I3X2pvSGNqNUFnVldSTEpIbGdHbTJCUEJYcmhCbXJLdmFHbUtuV21FUk4xRk9wV1U3UEo0QWdqMGZWSjBfd09JSVFySzFzb3A5cUF4NkNJM1FXeW1lZmpwejNSa3BLQzNpUE1Z?oc=5" target="_blank">FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQNnk1YzRhUkJNejhwRTNNZWdzZ3dnU3ZtWnJaMTlmYm9wT2U0Sm1keHlMTFJuZV9Rbkh0MExORWlBNEx5ajNKS3BRR094U0x0R1djeXBIRWNFTXhoa2pQbXEwOVNzSlRnd2dUUVByaDdPZXNWZEtqYnRKdENVWGlhWGgxaE1zT3UxczBua2lNdEZWYTlaWExDMWZ6UFBSN2lXSTRHSlhJOVBUM3B4aEN2SVpFQ3FEVUI0WlpraEU3ZlNXVmotdlE?oc=5" target="_blank">FDA Accepts Arcutis ZORYVE Application for Atopic Dermatitis in 3-Month-Old Infants</a>&nbsp;&nbsp;<font color="#6f6f6f">The Clinical Trial Vanguard</font>
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPQ1RFc3RUTGgtOWE1cEgzTUl4R3JxMEo5UGxNVGNtaW9WSHRjY0FHLTlLZU9DN244T1o4QmhKXzBoaDJxVjlMZUExT1JRQVpZYlIzYUZtVGpCT181ZHl0UTV4R05XeXh1ZUVqUUE1akFBaEptWUxOOHlBUUNNMTVfc053dFhjSkFEZmFfY1J2aFF3XzQ0SmVuZ2ZYV2ZTUjhOckZOSVVRQ0dVWWdFaVNsVW5LcGwybThvSzBHU3BCSHJGbUVXRjJSOE1PdmhCOEw4WDFLVk1FUW0?oc=5" target="_blank">FDA accepts mavacamten (Camzyos) application for adolescent obstructive hypertrophic cardiomyopathy</a>&nbsp;&nbsp;<font color="#6f6f6f">Contemporary Pediatrics</font>
<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxNUm9JTG52YTNkemVKOU9PVEE5RzRxQW9lLVpsazlabmE2Wk9veEpXb3ZnY2pGdWkxV1dxWVZveDFrTVBYNXNRYmhQck41enBvZWZmM3ZUWjBENlFYeXFWaGNWLUJCOXAtZHc5X09sNGlGeG1Kc2U1YkNJUVpweG9KX195cS1NR0huQ0JyNFdMUE1GSWZQUzNWUlF4SXJRUW54eWlvVERjUjNYb1I0MzZFTG9HeGxuRmEzWmJ0bldrQUcwYXpYeWthSXoxVllVWDVaRDBoT1FSQ2o0OU1CNk1MaFNTeVN3dWg0WjBsRjNxN0V4U0lRWTRfTDI2SzAwdXZfalJyUjh5TV9tS0taYnQyaG5WRUVXbXdu?oc=5" target="_blank">Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNbW9NSG5TQlpSZkgzTUZTTDJiUXVmY3FoTlJWYkVYWlF3OG5LbGpaek1HVk9LR2ZHUlFjRXBPdGRVQ2tGeHlSTDg3eEtwQ1NhQWZ6MFlrbno5S1JteTFwTXcteTBpU0RzWTBrTVg4VEppaDlpMkZ0RUI3TXlKVERWMUgxRXgwNFN4MUtJTGpGb25nNjI4YnZENlRMRQ?oc=5" target="_blank">FDA accepts filing for Moderna flu vaccine after swift rethink</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNNjNEbzdZcWcybEFoMXBNbm11bGpZSVlyX3l3b3dmcmRMWVdGNXhBWjlkTU8xZF9hUFdFWEl3X3pzWnhIc2NkYTNSdGNfNnZwME9URFdMUnpOV2JmVnBkV25Jb0lhbUdlZVk5RVNVR0VHdnlQNWpBTEktQkxHWHNQeWNUcjVDWHJFWlBsMXQzOE5iUjBzdnI3UHJsOXJfY1BwbV9YcFEzN0FaaTgzQkMzY0lsSEFOTEhXVFE?oc=5" target="_blank">FDA Accepts Merck Application to Expand ENFLONSIA Protection Into Second RSV Season</a>&nbsp;&nbsp;<font color="#6f6f6f">Infection Control Today</font>
<a href="https://news.google.com/rss/articles/CBMiwAJBVV95cUxNV2dxNWRtaWtCVk5kTXRWeFBfVzVBRkJ1QXltMVFKWE04Rm9IYVdxRkVQRGExR3RPd1NlM2EyalNDemt3Y0tVRV84MHZERlc3QjhYeG9aWWZJc3NYNTZtWHZfQ1VwUlFDalhHQ1F3OXVEM2tsa2tyZkY3cTNjbTNxdFhFYzdHcEFpX0Z1VXBTUDd1c3ZENUltV3lpbXpOa0RZSFhSdG5lZXBYUEVXM1hjSU5PX1VzZDYwN3pyOGUyXzdWaG9YR2YzaHpRaWF1b1FCV29HanZNNll6UGdoWm1sclB1Y0xZV3IyY01MTHVuV2lubTk2dGthVWhxb0hoN0ZpQ2RpaFdWMktKMUpmcnhsRHFHVlpLR3Z4SUc3bnVYcDFwWDlMZlhLa3BnZ0RsWkJVQ3VJRjhxd2pqUXp2WGR0RA?oc=5" target="_blank">FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPTUhPM19Pd1F5T2cwRzJiR25rU2hNNFVsMEc5VUxGNWZPYnN4VjlIN0Q5Nm9GQjNSTU9nclA5Xy1QSWxoMVVNcDNTQURnX0VhU2Rjc1NJZ3g4ZW1qOFVXcE40SUt3T2ZmZHY5WWNNRi04bWwzUjgxLW9sZmhNVzZWMFhuczlwNVJKUnQzZmtwaVBKVUp6WGE0azhZMlpjREIzXzlqX200bFdtSnQ2N2Rv?oc=5" target="_blank">FDA accepts roflumilast sNDA for AD in infants aged 3 to 24 months</a>&nbsp;&nbsp;<font color="#6f6f6f">Contemporary Pediatrics</font>
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQVnRTWlVKSjlYVlFDM1Q1RGtZQmd3TGV6LVVjUTVvc0hyakMzOVRJOEJzeGw0Q2N2WjNwamRlSS1qR0ZtZnBQeTBTeWpHMXFXenBRLWZiQ01WV2IwZ1hkaGVjSDNOc1BnREdLVFZMd2VZUVA2azhOSHp2c2djTjdNaWFXWXMtOWpWamFYSnJrWXVXc0tDdHRwQllXRHEwWmN4MGdr0gGoAUFVX3lxTE9BZTZGcXFOZkduN1FLcW1KYkxiUWdDTHBCWXdEekkwQWxqLXRSNHRJQjh5RFBLWWxjN2lFWVVwY2I3dkFhd0RCM2JpODR4Zml4UzZlYUQ2b2M3YWZwWWVBWXdKZE1BOWU0ZGxxMmI3OWRJbUhSYTdndjJ1QUtvTEJLMWN4QXNaNm1JbldCRkFqQ29LclpjT2tWWWh2LVh5ZHlPNW9mTW1IaA?oc=5" target="_blank">FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal</a>&nbsp;&nbsp;<font color="#6f6f6f">CNBC</font>
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQTkdtOFRmUmRlQTJGYmdIc1MyV3lqcjJGOW5EYklOWkVjaFg0aF81WmRtbUtfQWRtQjBIRlZ1RVhJdC1UZ09pRFVSR0Y3LWg3X0hHZmRnd2k3eHg1YUZkZ28zeTVsNFZsXzB0NS1jX0tMSXBMNDB2WkhyZWpnNHo1LXFTMDFJd0RjTjcyY0MweG5ZS1pNY1E?oc=5" target="_blank">FDA Accepts NDA for K-911 to Reduce Intraocular Pressure in Glaucoma</a>&nbsp;&nbsp;<font color="#6f6f6f">Ophthalmology Advisor</font>
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOS1lGZGdCQkU5aVFNc1M3aThtMHh6U0VPUHJ2R3p0dVUwSXVxSFo1WWs0bUM3aTJKQjF3RnI4VjNOVE1GT2JjUlYtSVFBYzV1Nm0xZFloWEc1OU5WRnJKSnVJMk5vS2h4Vmo5TUN1UHZ3T0d6SmJYN2dqc3U4MVdWUDRTU1lIdktma2pLUlFVZDRIVjEzNHA4SlJydHhIazFBUnppa2NjanRRZmtOUkNJRHVpOFFVUjhiNDlKcg?oc=5" target="_blank">FDA Accepts Application for Ziihera Combinations in HER2-Positive Gastroesophageal Cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOaTlyMUF1cVQyR09SZlFmakdfNXZBeW81M0VuaXBMemZGLWFkNXNMRHZPcnVjUkFoczFqQU41Y0NBVElXaDhqcGUxX2dHcVhfLXprbEJqbnIzMWRUYXMtMkgwSDlFWThuRlpTVnBiZkNpQXpNenpVeXc2LUY3OWhBeHJwQlhBRG9KUk9LNHlaaHI?oc=5" target="_blank">FDA Accepts Sandoz Applications for Generic Tirzepatide</a>&nbsp;&nbsp;<font color="#6f6f6f">Drug Topics</font>
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPSzFURTdpMjZwTlZxcExvUXhnSG44cEdxRGxlazBJZHpBaTRZemtkMFA4SmlCUFR6M2RvNW1ibEE5eG9OU3o1T3RDUTdENk5wRzlPazMxM2VrQWg2ZTlrVGgtWmw0SFJ6UEtaQUgyZ3NzeE1SWVV6ZHlxYUpjX2tWbERiYThRQWs4bVE?oc=5" target="_blank">FDA Accepts NDA for AXS-12 to Treat Cataplexy in Narcolepsy</a>&nbsp;&nbsp;<font color="#6f6f6f">Neurology Advisor</font>
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPMDBsRHJpWEJrV1RZMWJxN1l0ODROQ0xBa3RtWnFGZU5HSFEweGZFY3Z0dkFoY1Uta2FKeUswWU5NaDZZLUdEcE15TW50bThvZU5meE90T1hPUDVEbElkazJQN1Uxc0xZSk1PZXluR1R0TWJSdFBmNW9ZLTFOOTV1dTJNR0lYSFhlWFFraTBDTGpzUzVjVkdXZXktdmFqczIyWEJWT3dHUTJocDc4R3dXenB3MUo2bzM5RTFCTjd5eWtxeFQ5NER4YURXZW5pVzN0SFlNUA?oc=5" target="_blank">FDA Accepts sNDA and Grants Priority Review to AQNEURSA® for Ataxia-Telangiectasia</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMiogJBVV95cUxQb1o1VUhwQXR1M0dIMGFXdjNVbDNOZUxXTjNmbThQWjAza1JuM2ZLcUJFTjlHWk1qNDFuaWJtZ2ltUGk2dzJwUHpZanB4anR3V1pFS2dlSnJPZTVoNnJtczJPWVdHOTR4Tkw0M3Q1b3FGczhoN1Yyb0oxQWJKU1Z0T0tWVW9NQ3R5Z281dFZpcExnaWpLRmRkVW1xbXhmcC1JM0M1cGRRQi1BMHlITS1yZVNaaGNWaGJSSzZ2QlZCRDlBVlI3X282VW1pWGk0bUJlWTRiMlF3Zmo5d25aOTV4QURuUlIyUzNhSVZUcTcwMXBlUG9tX2FzU3JqQUxPbGhzNWt4TEU1Q0t2R29GWk0xb3h5Zk1meEVFaEx6SmdBMFo0dw?oc=5" target="_blank">U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>